Wells Fargo analyst Stan Berenshteyn lowered the firm’s price target on Omnicell (OMCL) to $40 from $49 and keeps an Equal Weight rating on the shares. The firm continues to see risks to Product revenue estimates in 2025 and elevated risks from health systems’ PnL.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OMCL: